Abstract: Objective To assess the efficacy and safety of solifenacin in patients with neurogenic detrusor overactivity (NDO). Methods 50 patients with NDO received solifenacin 5 mg/d. During the treatment period, the voiding diary, Patient Perception of Bladder Condition-Scale (PPBC-S) and side effects were recorded. Results 2 weeks and 12 weeks later, the volume of the catheterization every time increased from (224.2±15.7) ml at baseline to (302.6±23.3) ml and (301.3±21.1) ml (P<0.05); the volume of leakage every day decreased from (753.9±121.7) ml to (444.1±87.1) ml and (449.1±89.2) ml (P<0.05); PPBC-S score decreased from (5.12±0.072) to (4.36±0.073) and (4.36±0.068) (P<0.05). There were 3 cases (6%) with dry mouth, and no patients complained dry eyes and blurred vision. Conclusion Solifenacin is safe and effective, and can significantly improve the quality of life in patients with NDO.

Key words: neurogenic detrusor overactivity, solifenacin, efficacy, safety